scispace - formally typeset
S

Sverre E. Kjeldsen

Researcher at University of Oslo

Publications -  771
Citations -  95426

Sverre E. Kjeldsen is an academic researcher from University of Oslo. The author has contributed to research in topics: Blood pressure & Left ventricular hypertrophy. The author has an hindex of 94, co-authored 735 publications receiving 89059 citations. Previous affiliations of Sverre E. Kjeldsen include University of Michigan & Cornell University.

Papers
More filters
Journal ArticleDOI

Hypertension management during the COVID-19 pandemic: what can we learn for the future?

Michel Burnier, +4 more
- 15 Apr 2022 - 
Journal ArticleDOI

888-1 N-terminal pro brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: A LIFE study

Michael H. Olsen, +8 more
- 01 Mar 2004 - 
TL;DR: Nt-proBNP, more than Nt- ProANP, strongly predicts cardiovascular events in patients with hypertension and LV hypertrophy, especially in patients without diabetes or clinically overt cardiovascular disease.
Journal ArticleDOI

Hyper-responsiveness to low-dose epinephrine infusion in mild essential hypertension.

Sverre E. Kjeldsen, +6 more
- 01 Dec 1988 - 
TL;DR: The hypertensive patients showed a hyper-responsiveness to amounts of epinephrine which corresponds well to the plasma concentration achieved during psychological and physical activity.
Journal ArticleDOI

Relationship of diastolic function to new or persistent electrocardiographic left ventricular hypertrophy

Michael T. Tanoue, +3 more
- 05 May 2016 - 
TL;DR: In hypertensive patients undergoing antihypertensive therapy, persistence or development of Cornell product ECG LVH at year-3 follow-up is modestly associated with LV diastolic dysfunction, suggesting that diastolics dysfunction may be a mechanism via which changing ECGLVH influences HF risk.
Journal ArticleDOI

Renal Denervation After Symplicity HTN-3 - Back to Basics. Review of the Evidence.

Alexandre Persu, +5 more
- 01 Dec 2014 - 
TL;DR: The overall blood pressure lowering effect of RDN seems rather limited and the characteristics of true responders remain largely unknown, Accordingly, RDN is not ready for clinical practice.